Compare Global X Cybersecurity (BUG) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Cybersecurity vs Novavax Inc — how do they compare? Global X Cybersecurity trades at $42.42, while Novavax Inc trades at $8.45 (market cap $1.38B). The key difference: Global X Cybersecurity is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| BUG | NVAX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $41.99 | $11.19 |
52-Week Low | $23.30 | $6.22 |
Market Cap | — | $1.38B |
Enterprise Value | — | $889.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $8.91, down 4.5% today, with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong revenue of $1.12B in 2025 but negative equity of -$623.84M. Analyst consensus remains bullish with a $14.00 price target, though cash flow trends show ongoing operational losses. Recent news highlights shareholder dissent and market underperformance compared to peers.
The outlook is cautious; while valuation ratios like P/E of 3.14 appear attractive, persistent negative cash flow and high liabilities pose significant risks. Upside depends on sustainable profitability and execution amid competitive vaccine markets. Investors should weigh analyst optimism against fundamental weaknesses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Cybersecurity
BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.
Read more on BUG →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
